Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1) [PDF]
, 2009 Ganesh Raghu +7 more
openalex +1 more source
Future targets in the management of systemic sclerosis [PDF]
, 2017 CTDs—such as SSc and SLE and related rheumatic diseases such as RA—have complex, underlying pathogeneses that include fibrosis, vascular dysfunction, activation of the immune system and inflammation. Although some current therapies for SSc offer benefits
Matucci-Cerinic, M. +2 more
core
Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension [PDF]
, 2012 Anastasia Anthi +5 more
openalex +1 more source
Systemische Sklerose: Zielkriterien der Behandlung [PDF]
, 2018 Zusammenfassung: Die systemische Sklerose (SSc) ist eine Multisystemfibrose mit weltweitem Vorkommen und hoher Morbidität und Mortalität. Charakteristika der Erkrankung sind ausgedehnte Vaskulopathie, Entzündung, Autoimmunität und Fibrose ...
Distler, O. +4 more
core
Efficacy, safety and tolerability of bosentan as an adjuvant to sildenafil and sildenafil alone in persistant pulmonary hypertension of newborn (PPHN) [PDF]
, 2021 J Kumar +3 more
openalex +1 more source
Use of Bosentan in neonatal post cardiac surgery pulmonary hypertension
Annals of Pediatric Cardiology, 2009 We report the use of Bosentan in the post-operative period of a neonate with obstructed infradiaphragmatic total anomalous pulmonary venous connection and severe pulmonary arterial hypertension.
Pawar Ravindra +3 more
doaj
The effect of Bosentan on exercise capacity in Fontan patients; rationale and design for the TEMPO study [PDF]
, 2013 Anders Hebert +4 more
openalex +1 more source
Down patients with Eisenmenger syndrome: Is bosentan treatment an option? [PDF]
, 2008 M. G. J. Duffels +7 more
openalex +1 more source